(frequently updated)
Now that the VISION trial of Lu-177-PSMA-617 is no longer recruiting, some patients are wondering if they can still get PSMA-targeted radiopharmaceuticals in the US, without traveling to Germany, Australia, India, etc. Here is a list of trials that are active, still open to recruitment, or will soon be recruiting.
Unless otherwise noted, they are all for men who are:
- metastatic
- castration-resistant
- have had at least one taxane chemotherapy
- at least one of the advanced androgen receptor therapies (e.g., Zytiga, Xtandi, Erleada, or Nubeqa)
- no Xofigo
- PSMA-avid on a PSMA PET/CT scan
Radiopharmaceutical | Adjuvant drugs | Extra criteria | Recruitment status/ contact | Locations |
Lu-177-PSMA-617 LuCarbo | Carboplatin |
| Not yet recruiting | Dana-Farber, Boston
|
Lu-rhPSMA-10.1 |
| •Recurrent postRP •regionally positive on PSMA PET | recruiting | Emory, Atlanta |
Lu-177-JH20002 |
| •Advanced PCa | recruiting | •California •Florida •Michigan |
Lu-177-PSMA-617 PSMACare | 1. ADT 2.ARSi+ADT (ARSi=Zytiga, Xtandi,Erleada or Nubeqa) | •Metastatic with PSMA PET, but not with conventional imaging •CRPC •No prior ARSi or chemo | recruiting | TBD |
Lu-177-PNT2002 LUNAR | Before SBRT | Recurrent and oligometastatic | recruiting | UCLA |
Ac-225-J591 ACTION | SBRT, ADT if polymetastatic | Recurrent # mets | recruiting | Weill Cornell |
Lu-177-rhPSMA-10.1 |
| ±previous chemo | recruiting | •Maryland •St.Louis •Omaha •Mt Sinai-NYC |
Lu-177-PSMA-I&T |
| Chemo naïve, failed one hormonal | recruiting | • 56 locations |
Ac-225-PSMA-I&T TATCIST |
|
| Recruiting | • Houston |
Ac-225-J591 | | | recruiting | • Weill Cornell • Brooklyn Methodist |
Pluvicto+ONC392 (a CTL4 blocking immunotherapy) |
|
| recruiting | • NYU Langone • Columbia
|
Ac-225-J591 + Lu-177-PSMA- I&T | | | recruiting | • Weill Cornell • Brooklyn Methodist |
Ac-225-J591 | Keytruda | No chemo since castration resistant | recruiting | • Weill Cornell • Brooklyn Methodist • Dana Farber • Columbia |
Cu-67-SAR-bisPSMA SECuRE | | Previous chemo OK, not required | recruiting | • Johns Hopkins •Mayo Rochester •Mayo, AZ •Tulane, N.O. •Barnes Jewish, St. Louis •Omaha, NE •Weill Cornell |
Lu-177-PSMA-617 PSMAddition |
| mHSPC (M1 or N1) Treatment naive | Recruiting | • 174 sites |
Lu-177-PSMA-617 | Keytruda | No chemo since castration resistant | active, not recruiting | UCSF |
Lu-177-CTT1403 | | No Jevtana | active, not recruiting | UCSF |
Lu-177-PSMA-617 | | | Active, not recruiting | •Weill Cornell •Tulane |
Th-227-Antibody (see article) | | | active, not recruiting | • Royal Marsden (UK) • Finland • Tulane • MSK • Omaha, NE |
Lu-177-J591 | Ketoconazole | Prior RP or RT CRPC Non-metastatic | active, not recruiting | • Weill Cornell • USC • Georgetown • IU • U of Iowa • UPMC |
Lu-177-PSMA-R2 | | | Active, not recruiting | • Stanford • Yale • Tulane • Johns Hopkins • Mt Sinai • MD Anderson • U of Wisconsin • Phoenix |
Lu-177-PSMA-617 PSMAfore | | Chemo and immunotherapy naïve, failed one hormonal | Active, not recruiting (Phase 3 RCT) | • 72 sites |
Lu-177-PSMA-617 (VISION) | | | Active, not recruiting | • 84 locations Results expected August 2020 |
I-131-1095-MIPS (see article) | Xtandi | Chemo naïve Failed Zytiga | Active, not recruiting | • 17 locations Results expected December 2021 |
